The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Endometrial Neoplasms

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Endometrial Neoplasms


Psychiatry related information on Endometrial Neoplasms


High impact information on Endometrial Neoplasms


Chemical compound and disease context of Endometrial Neoplasms


Biological context of Endometrial Neoplasms


Anatomical context of Endometrial Neoplasms


Gene context of Endometrial Neoplasms


Analytical, diagnostic and therapeutic context of Endometrial Neoplasms


  1. Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium. Shapiro, S., Kaufman, D.W., Slone, D., Rosenberg, L., Miettinen, O.S., Stolley, P.D., Rosenshein, N.B., Watring, W.G., Leavitt, T., Knapp, R.C. N. Engl. J. Med. (1980) [Pubmed]
  2. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Bulun, S.E., Lin, Z., Imir, G., Amin, S., Demura, M., Yilmaz, B., Martin, R., Utsunomiya, H., Thung, S., Gurates, B., Tamura, M., Langoi, D., Deb, S. Pharmacol. Rev. (2005) [Pubmed]
  3. Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. Gal, D., Weiselberg, L., Runowicz, C.D. J. Natl. Cancer Inst. (1994) [Pubmed]
  4. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. Ali, I.U., Schriml, L.M., Dean, M. J. Natl. Cancer Inst. (1999) [Pubmed]
  5. Recreational physical activity and endometrial cancer risk. Littman, A.J., Voigt, L.F., Beresford, S.A., Weiss, N.S. Am. J. Epidemiol. (2001) [Pubmed]
  6. Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer. Comerci, J.T., Fields, A.L., Runowicz, C.D., Goldberg, G.L. Gynecol. Oncol. (1997) [Pubmed]
  7. Reduction of the individual cancer risk by physical exercise. Willer, A. Onkologie. (2003) [Pubmed]
  8. Estrogen replacement therapy in patients with endometrial cancer: a survey of prescription intention of Belgian gynecologists. Rozenberg, S., Vasquez, J.B. CA: a cancer journal for clinicians. (1999) [Pubmed]
  9. Familial endometrial cancer in female carriers of MSH6 germline mutations. Wijnen, J., de Leeuw, W., Vasen, H., van der Klift, H., Møller, P., Stormorken, A., Meijers-Heijboer, H., Lindhout, D., Menko, F., Vossen, S., Möslein, G., Tops, C., Bröcker-Vriends, A., Wu, Y., Hofstra, R., Sijmons, R., Cornelisse, C., Morreau, H., Fodde, R. Nat. Genet. (1999) [Pubmed]
  10. PTEN1 is frequently mutated in primary endometrial carcinomas. Kong, D., Suzuki, A., Zou, T.T., Sakurada, A., Kemp, L.W., Wakatsuki, S., Yokoyama, T., Yamakawa, H., Furukawa, T., Sato, M., Ohuchi, N., Sato, S., Yin, J., Wang, S., Abraham, J.M., Souza, R.F., Smolinski, K.N., Meltzer, S.J., Horii, A. Nat. Genet. (1997) [Pubmed]
  11. Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair. Risinger, J.I., Umar, A., Boyd, J., Berchuck, A., Kunkel, T.A., Barrett, J.C. Nat. Genet. (1996) [Pubmed]
  12. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. Shapiro, S., Kelly, J.P., Rosenberg, L., Kaufman, D.W., Helmrich, S.P., Rosenshein, N.B., Lewis, J.L., Knapp, R.C., Stolley, P.D., Schottenfeld, D. N. Engl. J. Med. (1985) [Pubmed]
  13. Treatment of advanced endometrial carcinoma with tamoxifen. Swenerton, K.D., White, G.W., Boyes, D.A. N. Engl. J. Med. (1979) [Pubmed]
  14. Increased risk of endometrial carcinoma among users of conjugated estrogens. Ziel, H.K., Finkle, W.D. N. Engl. J. Med. (1975) [Pubmed]
  15. Incidence of endometrial cancer in relation to the use of oral contraceptives. Weiss, N.S., Sayvetz, T.A. N. Engl. J. Med. (1980) [Pubmed]
  16. Postmenopausal hormone replacement therapy: scientific review. Nelson, H.D., Humphrey, L.L., Nygren, P., Teutsch, S.M., Allan, J.D. JAMA (2002) [Pubmed]
  17. Overexpression of hedgehog signaling molecules and its involvement in the proliferation of endometrial carcinoma cells. Feng, Y.Z., Shiozawa, T., Miyamoto, T., Kashima, H., Kurai, M., Suzuki, A., Ying-Song, J., Konishi, I. Clin. Cancer Res. (2007) [Pubmed]
  18. Crosstalk between NF-kappaB/p65 and beta-catenin/TCF4/p300 signalling pathways through alterations in GSK-3beta expression during trans-differentiation of endometrial carcinoma cells. Saegusa, M., Hashimura, M., Kuwata, T., Hamano, M., Okayasu, I. J. Pathol. (2007) [Pubmed]
  19. The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta. Colletta, A.A., Wakefield, L.M., Howell, F.V., Danielpour, D., Baum, M., Sporn, M.B. J. Clin. Invest. (1991) [Pubmed]
  20. Model for the molecular genetic diagnosis of endometrial cancer using K-ras mutation analysis. Al-Jehani, R.M., Jeyarajah, A.R., Hagen, B., Hogdall, E.V., Oram, D.H., Jacobs, I.J. J. Natl. Cancer Inst. (1998) [Pubmed]
  21. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Bergman, L., Beelen, M.L., Gallee, M.P., Hollema, H., Benraadt, J., van Leeuwen, F.E. Lancet (2000) [Pubmed]
  22. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Goodfellow, P.J., Buttin, B.M., Herzog, T.J., Rader, J.S., Gibb, R.K., Swisher, E., Look, K., Walls, K.C., Fan, M.Y., Mutch, D.G. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  23. Replacement estrogens and endometrial cancer. Jick, H., Watkins, R.N., Hunter, J.R., Dinan, B.J., Madsen, S., Rothman, K.J., Walker, A.M. N. Engl. J. Med. (1979) [Pubmed]
  24. Histopathologic distinctions in the relationship of estrogens and endometrial cancer. Horwitz, R.I., Feinstein, A.R., Vidone, R.A., Sommers, S.C., Robboy, S.J. JAMA (1981) [Pubmed]
  25. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. De Vivo, I., Huggins, G.S., Hankinson, S.E., Lescault, P.J., Boezen, M., Colditz, G.A., Hunter, D.J. Proc. Natl. Acad. Sci. U.S.A. (2002) [Pubmed]
  26. Rapid changes in specific estrogen binding elicited by cGMP or cAMP in cytosol from human endometrial cells. Fleming, H., Blumenthal, R., Gurpide, E. Proc. Natl. Acad. Sci. U.S.A. (1983) [Pubmed]
  27. Angiogenic role for glycodelin in tumorigenesis. Song, M., Ramaswamy, S., Ramachandran, S., Flowers, L.C., Horowitz, I.R., Rock, J.A., Parthasarathy, S. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  28. Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor. Kiaris, H., Chatzistamou, I., Schally, A.V., Halmos, G., Varga, J.L., Koutselini, H., Kalofoutis, A. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  29. Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors. Zhou, X.P., Kuismanen, S., Nystrom-Lahti, M., Peltomaki, P., Eng, C. Hum. Mol. Genet. (2002) [Pubmed]
  30. CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor alpha and estrogen receptor beta expressions. Sasaki, M., Tanaka, Y., Kaneuchi, M., Sakuragi, N., Dahiya, R. Cancer Res. (2003) [Pubmed]
  31. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. Vasen, H.F., Stormorken, A., Menko, F.H., Nagengast, F.M., Kleibeuker, J.H., Griffioen, G., Taal, B.G., Moller, P., Wijnen, J.T. J. Clin. Oncol. (2001) [Pubmed]
  32. Genetic variations in UGT1A1 and UGT2B7 and endometrial cancer risk. McGrath, M., Lepine, J., Lee, I.M., Villeneuve, L., Buring, J., Guillemette, C., De Vivo, I. Pharmacogenet. Genomics (2009) [Pubmed]
  33. Endometrial cancer and estrogen use. Report of a large case-control study. Antunes, C.M., Strolley, P.D., Rosenshein, N.B., Davies, J.L., Tonascia, J.A., Brown, C., Burnett, L., Rutledge, A., Pokempner, M., Garcia, R. N. Engl. J. Med. (1979) [Pubmed]
  34. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. Mutter, G.L., Lin, M.C., Fitzgerald, J.T., Kum, J.B., Baak, J.P., Lees, J.A., Weng, L.P., Eng, C. J. Natl. Cancer Inst. (2000) [Pubmed]
  35. Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Sasaki, M., Dharia, A., Oh, B.R., Tanaka, Y., Fujimoto, S., Dahiya, R. Cancer Res. (2001) [Pubmed]
  36. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Thigpen, J.T., Blessing, J.A., DiSaia, P.J., Yordan, E., Carson, L.F., Evers, C. J. Clin. Oncol. (1994) [Pubmed]
  37. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Xiong, Y., Dowdy, S.C., Podratz, K.C., Jin, F., Attewell, J.R., Eberhardt, N.L., Jiang, S.W. Cancer Res. (2005) [Pubmed]
WikiGenes - Universities